HanAll Biopharma Co., Ltd.

The South Korea government plans to improve the transparency and objectivity of standards for pharma firms to officially qualify as “innovative” and eligible for special policy treatment, amid foreign

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Helsinn Extends Akynzeo Marketing

OKYO Pharma Limited is ready to move its dry eye disease candidate, OK-101, into Phase III and asserted that the efficacy and safety profile it has seen so far might position OK-101 to take a market-

At first glance, the curious thing about the failure of Sylentis S.A.U. ’s tivanisiran in a Phase III trial in dry-eye disease associated with Sjögren’s syndrome is that it follows a late-stage hit i